03:44 , Jul 31, 2015 |  BC Extra  |  Financial News

Zogenix raises $85.5M in follow-on

Zogenix Inc. (NASDAQ:ZGNX) raised $85.5 million through the sale of 4.8 million shares at $18 in a follow-on underwritten by Leerink; Stifel; Oppenheimer; and Brean Capital. The company proposed the offering after market on Tuesday,...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Company News

Brabant Pharma, Zogenix deal

In late October, Zogenix acquired Brabant for $20 million in cash and $15 million in stock, plus up to $50 million in regulatory milestone payments and up to $45 million in royalty payments. Zogenix said...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Brabafen regulatory update

Brabant said FDA and the European Commission granted Orphan Drug designation to Brabafen to treat children with severe myoclonic infant epilepsy (Dravet syndrome), a rare and severe form of infantile-onset, drug-resistant pediatric epilepsy syndrome. The...